Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (338)	1/23/2012 3:49:18 PM
From: steve kammerer	Read Replies (1) \| Respond to of 363

http://seekingalpha.com/article/321380-2-high-risk-high-reward-biotechs-that-could-double How's this sound? NPS Pharmaceuticals ( NPSP), a clinical-stage biopharmaceutical company, engages in the development specialty therapeutics for gastrointestinal and endocrine disorders. The company's primary clinical programs consist of two therapeutic proteins to restore or replace biological functions, including GATTEX (teduglutide) that is in Phase 3 clinical development and is intended for parenteral nutrition dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection), which is in Phase 3 clinical development and is intended for use as a hormone replacement therapy for hypoparathyroidism." (Business Description from Yahoo Finance) 4 reasons NPSP is worth a gamble at under $7 a share: Insiders are showing confidence by gobbling up 70,000 shares in fourth quarter of 2011. The median analysts' price target is more than double the current price at $14 a share. S&P has a "Buy" rating and a $13 price target on the stock. Gilead Science's ( GILD) acquisition of Pharmasset has kicked off an M&A surge in the biotech space. Given NPS's late stage pipeline and valuation, it would hardly be a surprise to see this company be bought out at a large premium. The company has plenty of cash on the balance sheet and improving cash flow, so it has the financial strength to easily survive until some of its late stage drugs are approved.